News - Pfizer, Patents

Filter

Current filters:

PfizerPatents

Popular Filters

1 to 25 of 33 results

Mylan challenges FDA ruling on exclusivity relating to generic celecoxib

Mylan challenges FDA ruling on exclusivity relating to generic celecoxib

27-04-2014

US generics firm Mylan has filed suit against the US Food and Drug Administration, challenging the agency's…

CelebrexGenericsInflammatory diseasesLegalMylanPatentsPfizer

Actavis settles Celebrex patent challenge with Pfizer

24-04-2014

Ireland-headquartered generic major Actavis has entered into an agreement with US pharma giant Pfizer…

ActavisAnti-Arthritics/RheumaticsCelebrexGenericsLegalPatentsPfizerUSA

Teva and Pfizer settle patent litigation over Celebrex

17-04-2014

Israel-based Teva Pharmaceutical Industries says that its US subsidiary has settled a law suit with US…

Anti-Arthritics/RheumaticsCelebrexGenericsNorth AmericaPatentsPfizerTeva Pharmaceutical IndustriesUSA

India’s IPAB upholds Pfizer’s Detrol patent

India’s IPAB upholds Pfizer’s Detrol patent

27-03-2014

In a positive development for US drug giant Pfizer, India's Intellectual Property Appellate Board (IPAB)…

Asia-PacificDetrolGenito-urinaryIndiaPatentsPfizerPharmaceuticalRanbaxy Laboratories

Pfizer to appeal Court decision on Celebrex reissue patent

Pfizer to appeal Court decision on Celebrex reissue patent

13-03-2014

US pharma behemoth Pfizer confirmed today that the US District Court for the Eastern District of Virginia…

Anti-Arthritics/RheumaticsCelebrexLegalNorth AmericaPatentsPfizerPharmaceuticalUSA

US Appeals Court upholds Pfizer’s Lyrica patent until 2018

US Appeals Court upholds Pfizer’s Lyrica patent until 2018

07-02-2014

US pharma giant Pfizer has prevailed in protecting intellectual property for its blockbuster drug Lyrica…

LegalLyricaPatentsPfizerPharmaceuticalTeva Pharmaceutical Industries

Mylan enters Tarceva settlement agreement

24-07-2013

US generics firm Mylan (Nasdaq: MYL) has entered into a settlement agreement with OSI Pharmaceuticals,…

GenentechGenericsLegalMylan LaboratoriesNorth AmericaOncologyOSI PharmaceuticalsPatentsPfizerTarceva

Impax Labs confirms patent challenge to Pfizer/UCB's Toviaz

04-07-2013

US specialty drugmaker Impax Laboratories (Nasdaq: IPXL) yesterday confirmed that it has initiated a…

Gastro-intestinalsGenericsImpax LaboratoriesNorth AmericaPatentsPfizerToviazUCB

InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against

17-06-2013

InSite Vision (OTC BB: INSV) that it will US pharma giants join Merck & CO (NYSE: MRK) and Pfizer (NYSE:…

AzaSiteGenericsInSite VisionLegalMerck & CoMylan LaboratoriesNorth AmericaOphthalmicsPatentsPfizerPharmaceutical

Indian IPAB provides relief for Pfizer in Sutent patent revocation case

05-06-2013

India's Intellectual Property Appellate Board (IPAB) has provided global pharma behemoth Pfizer (NYSE:…

Asia-PacificCiplaPatentsPfizerPharmaceuticalSutent

Ranbaxy in deal with Alembic to market bioequivalent Pristiq in USA

05-03-2013

The US subsidiary of India's largest drugmaker, Ranbaxy Laboratories (AB: BO), which is majority owned…

Alembic PharmaceuticalsDaiichi SankyoGenericsLicensingMarkets & MarketingNeurologicalNorth AmericaPatentsPfizerPristiqRanbaxy Laboratories

Cipla prevails in Sutent patent dispute with Pfizer; puts hold on Cipla Medpro deal

12-02-2013

The Indian patent office has again ruled in favor of domestic drugmaker Cipla (BSE: 500087), reinstating…

Asia-PacificCiplaCipla MedproGenericsLegalMergers & AcquisitionsOncologyPatentsPfizerRest of the WorldSutent

Pfizer prevails in Rapamune patent dispute with Watson

01-02-2013

Global pharma behemoth Pfizer (NYSE: PFE) says that the US District Court for the District of Delaware…

ActavisGenericsImmunologicalsLegalNorth AmericaPatentsPfizerPharmaceuticalRapamuneWatson Pharmaceuticals

India's Cipla cuts prices of three cancer drugs

12-11-2012

Following what Indian drugmaker Cipla (BSE: 500087) said was an "overwhelming response" on the price…

Asia-PacificcapecitabineCipladocetaxelerlotinibGenericsOncologyPatentsPfizerPharmaceuticalPricingSunitinib MalateSutent

Canada's Supreme Court paves way for generic Viagra

09-11-2012

There was disappointing news for global pharma behemoth Pfizer (NYSE: PFE) yesterday, when the Canadian…

GenericsLegalMen's HealthNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesViagra

Another negative Indian patent ruling, this time for Pfizer's Sutent

08-10-2012

In yet another setback for research-based pharmaceutical companies, last week the Indian patent office…

Asia-PacificCiplaGenericsLegalNatco PharmaOncologyPatentsPfizerPharmaceuticalSutent

Pfizer links with SFJ Pharma for dacomitinib trial; settles with Mylan

10-09-2012

SFJ Pharmaceuticals Group, a global drug development group of companies which provides a unique co-development…

dacomitinibDetrol LAGastro-intestinalsGenericsLegalMylan LaboratoriesNorth AmericaOncologyPatentsPfizerPharmaceuticalResearchSFJ Pharmaceuticals

US FTC goes after Pharma on two fronts relating to patent agreements

14-08-2012

In what appears to be a two pronged attack on pharmaceutical industry practices, the US Federal Trade…

Effexor XRGenericsLegalNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesWyeth

US Court confirms Pfizer patents on Lyrica valid through 2018

23-07-2012

The US District Court for the District of Delaware upheld the Pfizer (NYSE: PFE) composition of matter…

GenericsLegalLyricaNeurologicalNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical Industries

Watson challenges Pfizer's Pristiq patent

26-06-2012

US generics drugmaker Watson Pharmaceuticals (NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories,…

GenericsNeurologicalNorth AmericaPatentsPfizerPharmaceuticalPristiqRegulationWatson Pharmaceuticals

1 to 25 of 33 results

Back to top